Status:

COMPLETED

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

Lead Sponsor:

Changhai Hospital

Conditions:

Sepsis

Eligibility:

All Genders

18+ years

Brief Summary

* Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis. * HSPA12B is primarily...

Eligibility Criteria

Inclusion

  • Adult patients
  • Patients meet the diagnostic criteria according to the grouping

Exclusion

  • patients without informed consent
  • patients who were undergoing continuous renal replacement therapy before sampling
  • patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

Key Trial Info

Start Date :

May 1 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2013

Estimated Enrollment :

118 Patients enrolled

Trial Details

Trial ID

NCT01847248

Start Date

May 1 2011

End Date

October 1 2013

Last Update

November 25 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital

Shanghai, China, 200433

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis | DecenTrialz